New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...
clinicaltrialsarena5d
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).
Business Wire4d
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD) in the Difficult-to-Treat Head and Neck Region
1 “Atopic dermatitis often affects multiple regions of the body but can be exceptionally burdensome and difficult to treat in the head and neck,” said Kreesten Meldgaard Madsen, Chief Developm ...
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis
Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...
Investing6d
RINVOQ shows promise in atopic dermatitis head and neck treatment
Atopic dermatitis, especially when affecting visible areas like the head and neck, can significantly impact patients' quality of life. Studies such as UP-TAINED and AD-VISE have indicated that a ...
Eczema Isn’t One-Size-Fits-All—Here’s Why That Matters for People of Color, and What a Doctor Wants You To Know
Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...
Stockhouse6d
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity of disease in the head and neck region at ...
Investing6d
RINVOQ shows promise in atopic dermatitis head and neck treatment
AbbVie (NYSE: NYSE:ABBV) has released a new post-hoc analysis from Phase 3 studies, demonstrating the efficacy of its drug RINVOQ (upadacitinib) in treating moderate-to-severe atopic dermatitis (AD), ...
Mena FN6d
New Analysis Demonstrates The Efficacy Of RINVOQ® (Upadacitinib) In Atopic Dermatitis With Varying Degrees Of Severity In Head And Neck Involvement
efficacy of RINVOQ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results in skin clearance, itch resolution ...